Yes, there is an expedited review process in Hong Kong. Formalized in January 2022, the Expedited Approval Scheme (previously a trial scheme) provides qualifying Class II, III, and IV applications with a quicker review. Products will need to have 2 Reference Country approvals, no serious adverse events, and no ongoing adverse events. Reference Countries include the US, Canada, Europe, Australia, Japan, China, and Korea (trial until Dec. 31, 2022) The MDD’s formal guidance can be found here under GN-02. Official review times have not been provided yet but the MDD assures manufacturers that the applications will receive a more expedited review.